La Jolla Pharmaceutical Company to Provide Corporate Overview at the JMP Securities Life Science Conference 2015
June 17 2015 - 7:00AM
Business Wire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or
La Jolla), a leader in the development of innovative therapies
intended to significantly improve outcomes in patients suffering
from life-threatening diseases, today announced that the Company
will provide a corporate overview at the JMP Securities Life
Science Conference 2015 taking place June 23–24 in New York
City.
JMP Securities Life Science Conference
2015 Presentation Details
Date: Wednesday, June 24, 2015 Time: 9:30 a.m.
Eastern Time Location: Fontainebleau Room @ The St. Regis New York
Webcast:
LJPC Webcast Link
A live webcast of the presentation will also be available in the
Investor Relations section of La Jolla’s website at www.ljpc.com. A
replay of the presentation will be available on La Jolla’s website
for 30 days following the event.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company
focused on the discovery, development and commercialization of
innovative therapies intended to significantly improve outcomes in
patients suffering from life-threatening diseases. The Company has
several product candidates in development. LJPC-501 is La Jolla’s
proprietary formulation of angiotensin II for the potential
treatment of catecholamine-resistant hypotension and hepatorenal
syndrome. LJPC-401 is La Jolla’s novel formulation of hepcidin for
the potential treatment of conditions characterized by iron
overload, such as hemochromatosis and beta thalassemia. LJPC-30Sa
and LJPC-30Sb are La Jolla’s next-generation gentamicin derivatives
for the potential treatment of serious bacterial infections and
rare genetic disorders, such as cystic fibrosis and Duchenne
muscular dystrophy. For more information on La Jolla, please visit
www.ljpc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150617005422/en/
La Jolla Pharmaceutical CompanyGeorge F. Tidmarsh, M.D.,
Ph.D.President & Chief Executive
Officer858-207-4264gtidmarsh@ljpc.comandDennis M. MulroyChief
Financial Officer858-433-6839dmulroy@ljpc.com
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Apr 2024 to May 2024
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about La Jolla Pharmaceutical Company (NASDAQ): 0 recent articles
More LA Jolla Pharmaceutical Company (MM) News Articles